Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758607 | 1.00 | AKR1B1 (0.34) | AKR1B1GAAHTTSMN1; SMN2HTR5A | |
| SCHEMBL25758520 | 0.86 | CYP1A2 (0.37) | AKR1B1GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL25758612 | 0.86 | CYP1A2 (0.37) | AKR1B1GAAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL25758648 | 0.81 | HTR5A (0.32) | HTR5AHTR2AHTR2C | |
| SCHEMBL25758517 | 0.81 | AKR1B1 (0.35) | AKR1B1HTR5AHTR2AHTR2C | |
| SCHEMBL25758561 | 0.81 | HTR5A (0.32) | HTR5AHTR2AHTR2C | |
| SCHEMBL25758600 | 0.81 | AKR1B1 (0.35) | AKR1B1HTR5AHTR2AHTR2C | |
| SCHEMBL24029215 | 0.79 | AKR1B1 (0.43) | AKR1B1GAAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL23835847 | 0.79 | AKR1B1 (0.43) | AKR1B1GAAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL15221224 | 0.78 | AKR1B1 (0.37) | AKR1B1GAAHTTSMN1; SMN2HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | AKR1B1 3400/4885GAA 329/4885HTT 2625/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | AKR1B1 3391/4885GAA 326/4885HTT 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.